BioNTech SE has a total of 52 patent applications. It increased the IP activity by 850.0%. Its first patent ever was published in 2004. It filed its patents most often in Australia, EPO (European Patent Office) and Canada. Its main competitors in its focus markets pharmaceuticals, biotechnology and organic fine chemistry are GENENTECH INC, ALITALO KARI and MEDIMMUNE INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 13 | |
#2 | EPO (European Patent Office) | 11 | |
#3 | Canada | 5 | |
#4 | United States | 4 | |
#5 | Brazil | 3 | |
#6 | Republic of Korea | 3 | |
#7 | Singapore | 3 | |
#8 | WIPO (World Intellectual Property Organization) | 3 | |
#9 | Israel | 2 | |
#10 | Japan | 2 | |
#11 | Hungary | 1 | |
#12 | Serbia | 1 | |
#13 | Russian Federation | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Organic fine chemistry | |
#4 | Measurement | |
#5 | Environmental technology | |
#6 | Medical technology | |
#7 | Foods and drinks |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Peptides | |
#4 | Microorganisms | |
#5 | Heterocyclic compounds | |
#6 | Analysing materials | |
#7 | Measuring microorganism processes | |
#8 | Climate change adaptation technologies | |
#9 | Electrotherapy | |
#10 | Enzymes |
# | Name | Total Patents |
---|---|---|
#1 | Sahin Ugur | 31 |
#2 | Henry Christophe | 13 |
#3 | Parren Paul | 10 |
#4 | Gieseke Friederike | 9 |
#5 | Altintas Isil | 9 |
#6 | Satijn David | 9 |
#7 | Fiedler Markus | 9 |
#8 | Daneschdar Matin | 7 |
#9 | Türeci Özlem | 6 |
#10 | Schmoldt Hans-Ulrich | 6 |
Publication | Filing date | Title |
---|---|---|
WO2020178434A1 | Process for the preparation of a substituted imidazoquinoline | |
KR20200050964A | Substituted imidazoquinoline as an agonist of TLR7 | |
WO2019233605A1 | Compositions and methods for diagnosis and treatment of cancer | |
AU2016203425A1 | Genetic products differentially expressed in tumors and the use thereof | |
AU2015255252A1 | Methods and compositions for diagnosis and treatment of cancer | |
EP3777882A1 | Tumor antigens for determining cancer therapy | |
US2017151349A1 | Particles comprising protamine and RNA in combination with endosome destabilizing agents | |
EP2920209A1 | Agents for treatment of claudin expressing cancer diseases |